Search - tctmd.com

Displaying 621 - 640 of 643

Sort: Relevancy | Date

News Daily News

美国和欧洲的心衰指南提倡使用两个新疗法

L.A. McKeown

May 24, 2016

News Daily News

US and European Heart Failure Guidelines Advocate Use of Two New Therapies

L.A. McKeown

May 24, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Daily News

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Michael O'Riordan

March 25, 2016

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Industry News

scPharmaceuticals Announces Positive Results from Pivotal Trial of its Novel Subcutaneous Furosemide Formulation in Patients with Heart Failure

November 03, 2015

News Industry News

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

October 27, 2015

News Industry News

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

October 26, 2015

News Industry News

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

September 28, 2015

News Conference News ESC 2015

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Industry News

ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy

July 27, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Daily News

比伐卢定加 GPI 可减少接受 PCI 的心衰患者的出血和死亡率

June 09, 2015

News Daily News

Bivalirudina + GPI Reduce las Hemorragias y Mortalidad de Pacientes con ICC sometidos a PCI

June 09, 2015

News Daily News

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

June 09, 2015

News Industry News

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

June 02, 2015

News Daily News

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

Todd Neale

January 28, 2015

News Daily News

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

Todd Neale

January 28, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

Advertisement

美国和欧洲的心衰指南提倡使用两个新疗法

US and European Heart Failure Guidelines Advocate Use of Two New Therapies

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

scPharmaceuticals Announces Positive Results from Pivotal Trial of its Novel Subcutaneous Furosemide Formulation in Patients with Heart Failure

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

比伐卢定加 GPI 可减少接受 PCI 的心衰患者的出血和死亡率

Bivalirudina + GPI Reduce las Hemorragias y Mortalidad de Pacientes con ICC sometidos a PCI

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content